Clinical Trials Logo

Pancreatic Neoplasms clinical trials

View clinical trials related to Pancreatic Neoplasms.

Filter by:

NCT ID: NCT03738787 Recruiting - Clinical trials for Postoperative Complications

Treatment of the Pancreatic Stump With Neoprene®-Based Glue After High-risk Pancreatoduodenectomy

Start date: January 1, 2015
Phase: Phase 2
Study type: Interventional

The study evaluates the safety and efficacy of Neoprene-based glue in the management of pancreatic stump after pancreatoduodenectomy (PD) in patients at high risk for pancreatic fistula and early neoplastic recurrence, compared with a population of patients at conventional risk.

NCT ID: NCT03738280 Recruiting - Clinical trials for Endoscopic Ultrasound

Non-hypovascular Solid Pancreatic Lesions: Role of EUS

LE-VASC
Start date: May 1, 2018
Phase:
Study type: Observational

Vascular pattern of solid pancreatic lesions (SPLs) has been investigated by different abdominal imaging modalities and by contrast-enhanced endoscopic ultrasonography (CE-EUS). Compared with surrounding pancreatic parenchyma three different patterns have been described: hypo-, iso-, and hypervascular. The majority of SPLs are hypovascular, and the diagnostic relevance of hypoenhanced pattern to predict pancreatic adenocarcinoma (PDAC) is well established. Differently, iso- and hypervascular pattern is not specific and can be expressed by several SPLs, with different clinical behavior and management. To date, poor is know about the role of EUS in differential diagnosis of non-hypovascular SPLs and features associated with malignancy.

NCT ID: NCT03726021 Recruiting - Overall Survival Clinical Trials

Study of Irinotecan,Oxaliplatin, and S1 in Patients With Advanced Pancreatic Cancer

Start date: January 26, 2018
Phase: Phase 2
Study type: Interventional

To identify the efficiency of Irinotecan, Oxaliplatin, and S1 in patients with previously untreated local regional or metastatic pancreatic cancer.

NCT ID: NCT03724994 Recruiting - Pancreatic Cancer Clinical Trials

Chemotherapy, Host Response and Molecular Dynamics in Periampullary Cancer

CHAMP
Start date: September 1, 2018
Phase:
Study type: Observational [Patient Registry]

The CHAMP (Chemotherapy, Host response And Molecular dynamics in Periampullary cancer) study is a prospective, single-arm observational study that started Sept 1 2018. Patients diagnosed with pancreatic or other periampullary adenocarcinoma undergoing adjuvant och palliative chemotherapy are invited to participate. The study will examine the tumors' molecular dynamics and how this may change over time and with treatment. Primary endpoint will be overall survival, secondary endpoints will be disease specific survival, time to progression, and quality of life. We estimate that 90 patients will be included in the study per year.

NCT ID: NCT03724435 Not yet recruiting - Pancreatic Cancer Clinical Trials

Focused Ultrasound for the Treatment of Pancreatic Cancer - an International Registry

ARRAY
Start date: December 3, 2018
Phase:
Study type: Observational [Patient Registry]

This pancreatic cancer registry aims to collect information on people around the world who select focused ultrasound (FUS) as part of their treatment for pancreatic cancer to learn about the performance of the focused ultrasound technology and health outcomes; the impact of focused ultrasound on your overall health; and provide an understanding of the current care for pancreatic cancer.

NCT ID: NCT03723915 Not yet recruiting - Clinical trials for Pancreatic Adenocarcinoma

Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer

Start date: November 30, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies the side effects and how well pembrolizumab in combination with pelareorep work in treating patients with pancreatic cancer that has spread to other parts of the body. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. A virus, called reovirus (pelareorep), which has been changed in a certain way, may be able to kill tumor cells without damaging normal cells. Giving pembrolizumab in combination with pelareorep may work better in treating patients with advanced pancreatic cancer.

NCT ID: NCT03721744 Not yet recruiting - Clinical trials for Metastatic Pancreatic Cancer

A Study of Napabucasin(GB201) in Combination With Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic Cancer

Start date: October 2018
Phase: Phase 3
Study type: Interventional

This is a Phase III Randomized, Open-Label Clinical Study of Napabucasin (GB201) in Combination with Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Metastatic Pancreatic Cancer Following Front-Line Chemotherapy Failure

NCT ID: NCT03719716 Recruiting - Cancer of Pancreas Clinical Trials

Early Support in Primary Care for People Starting Treatment for Cancer

GI-ACP
Start date: October 15, 2018
Phase: N/A
Study type: Interventional

This is a feasibility, randomised controlled trial (RCT) of a person-centred care planning intervention involving patients recently diagnosed with a poor prognosis cancer who are starting a palliative oncology treatment in a Scottish regional cancer centre.

NCT ID: NCT03718650 Not yet recruiting - Pancreatic Cancer Clinical Trials

Total Tumor Mapping (TTM) for Resectable Pancreatic Cancer

Start date: January 1, 2019
Phase: Early Phase 1
Study type: Interventional

At present there is no validated prognostic tool for patients with resectable pancreatic cancer (RPC) to determine how best to tailor individual therapy. This study is to see if tumor features in blood and imaging prior to surgery correspond with tumor heterogeneity in the specimen after surgery.

NCT ID: NCT03717298 Not yet recruiting - Pancreatic Cancer Clinical Trials

Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma

Start date: October 30, 2018
Phase: Phase 2
Study type: Interventional

The investigators hypothesized that with the administration of the nutritional supplement Ocoxin-Viusid® is expected to improve the quality of life and enhance tolerance to chemotherapy in at least 70% of patients diagnosed with advanced pancreatic adenocarcinoma, treated at the "Hermanos Ameijeiras" Surgical Clinical Hospital. Phase II clinical trial, open, multicenter, nonrandomized.